Zai Lab Limited (ZLAB) 10-Q2023 Q1 Quarterly report

Filed: 9 May 23, 4:10pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Acetylcholine, Acinetobacter, adenocarcinoma, advertise, Advertising, Antimicrobial, Asia, assert, assume, ATTACK, average, behavior, biliary, BMTPZ, confirmatory, consideration, content, Coverage, COVID, cycle, defend, display, domain, ductal, eased, elaborate, employer, employment, encouraging, endorsement, espionage, evolving, franchise, fullest, furnish, growing, Harvard, imply, indemnification, indemnify, infection, innovaTV, Innoviva, Internet, KRAZATI, leave, leverage, lifted, ligand, logo, lymphoma, MediLink, midpoint, Muscarinic, NCCN, neck, neuroendocrine, Notch, officially, Pacific, partnership, Plenary, priority, Province, reconcile, reinforcing, reiterate, role, salary, signify, simplified, sponsorship, susceptible, traceability, tract, trademark, unanimously, unrealized, unregistered, urgent, urgently, Vice, view, weighted

Removed: abide, Accelerating, accept, account, Accountable, active, adjusted, adult, allocation, America, analogizing, anticipated, applying, argenx, arrangement, assessing, assignee, assistance, ASU, auditor, authorized, aware, beginning, beneficial, Bermuda, biodefense, block, candidate, case, combination, comment, compete, competition, conclude, conclusively, conducted, consecutive, contingently, continuing, contractually, costlier, Council, Creating, debtor, delay, delisted, delisting, Depositary, designation, detailed, difficult, discount, disease, divided, draft, efficacy, efgartigimod, eligible, EMA, enacted, entail, entertainment, environment, evaluated, evaluating, event, exclusive, face, fail, FASB, field, firm, force, foregoing, formally, found, fragment, framework, generated, GMP, headquartered, HFCAA, hinder, House, Huizheng, identified, impairment, inadvertently, independent, ingredient, inject, inspect, inspected, inspection, investigate, issuance, issuer, jurisdiction, key, KPMG, lack, largely, lease, legislation, legislative, limit, LLP, longer, lower, marketability, marketed, median, niraparib, nonrecurring, noted, omadacycline, operation, ovarian, oversight, par, Paratek, participation, passed, PCAOB, platform, predicted, preventative, principally, prohibit, prohibiting, proprietary, Quarterly, randomized, ranging, ratio, reach, regulate, repotrectinib, resolution, restriction, retrospectively, sale, scheduled, section, Senate, sensitive, sentiment, standard, stipulated, Strength, subdivided, Subdivision, subsequently, survival, territory, therapeutic, therapy, threatened, titled, Topic, transparency, treated, Trend, unable, unclear, undermined, unissued, valid, volume, VYVGART, work

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ZLAB transcripts

ZLAB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification by the Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 of Zai Lab Limited (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Billy Cho, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: May 9, 2023			/s/ Billy Cho
			Billy Cho
			Chief Financial Officer
			(Principal Financial and Accounting Officer)